secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001628280-23-026988
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q2 2023: AVTX-002 misses Phase 2 asthma endpoint; cash $6.3M, debt forbearance
--------------------------------------------------------------------------------

- AVTX-002 did not meet primary endpoint (asthma-related events) in Phase 2 PEAK non-eosinophilic asthma trial.
- Net loss of $8.2M for Q2 2023; product revenue of $643K.
- Cash $6.3M at June 30, 2023, down from $13.2M at Dec 31, 2022; $6M loan prepaid in June.
- Forbearance agreement with lenders until Aug 15, 2023 due to material adverse change event of default.
- Exploring sale or out-licensing of assets; non-binding LOI for AVTX-801/802/803.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/0001628280-23-026988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/avtx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-026988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer